Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data
Robert A. Jolly(Eli Lilly (United States)), Raechel Puglisi(Health and Environmental Sciences Institute), Sheroy Minocherhomji(Eli Lilly (United States)), Mark W. Powley(Merck & Co., Inc., Rahway, NJ, USA (United States)), Raphael Nudelman(Teva Pharmaceuticals (Israel)), David J. Ponting(University of Leeds), Joel P. Bercu(Eli Lilly (United States)), Andreas Czich(Sanofi (Germany)), Rachael E. Tennant, Cheryl A. Hobbs(Pivot Bio (United States)), Zhanna Sobol(Pfizer (United States)), Connie L. Chen(Health and Environmental Sciences Institute), Andreas Zeller(Roche (Switzerland)), Patricia A. Escobar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anthony M. Lynch(Age UK), Maik Schuler(Pfizer (United States)), George Johnson(Swansea University), Yi Hui Yang(AbbVie (United States)), Alejandra Trejo-Martin(Gilead Sciences (United States)), Paul B. White(Health Canada), Gregory R. Ott(Teva Pharmaceuticals (United States))
Cited by 3
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
The in vivo Pig-a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) Workgroup
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2014|156